69 related articles for article (PubMed ID: 23389497)
1. L-asparaginase: long-term results of a randomized trial of the effect of additional 3 doses during consolidation treatment in the Indonesian WK-ALL-2000 protocol.
Widjajanto PH; Sumadiono S; Purwanto I; Sutaryo S; Veerman AJ
J Pediatr Hematol Oncol; 2013 Nov; 35(8):597-602. PubMed ID: 23389497
[TBL] [Abstract][Full Text] [Related]
2. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial.
Place AE; Stevenson KE; Vrooman LM; Harris MH; Hunt SK; O'Brien JE; Supko JG; Asselin BL; Athale UH; Clavell LA; Cole PD; Kelly KM; Laverdiere C; Leclerc JM; Michon B; Schorin MA; Welch JJ; Lipshultz SE; Kutok JL; Blonquist TM; Neuberg DS; Sallan SE; Silverman LB
Lancet Oncol; 2015 Dec; 16(16):1677-90. PubMed ID: 26549586
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
[TBL] [Abstract][Full Text] [Related]
4. Prolonged
Mondelaers V; Suciu S; De Moerloose B; Ferster A; Mazingue F; Plat G; Yakouben K; Uyttebroeck A; Lutz P; Costa V; Sirvent N; Plouvier E; Munzer M; Poirée M; Minckes O; Millot F; Plantaz D; Maes P; Hoyoux C; Cavé H; Rohrlich P; Bertrand Y; Benoit Y;
Haematologica; 2017 Oct; 102(10):1727-1738. PubMed ID: 28751566
[TBL] [Abstract][Full Text] [Related]
5. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
6. Effect of protracted high-dose L-asparaginase given as a second exposure in a Berlin-Frankfurt-Münster-based treatment: results of the randomized 9102 intermediate-risk childhood acute lymphoblastic leukemia study--a report from the Associazione Italiana Ematologia Oncologia Pediatrica.
Rizzari C; Valsecchi MG; Aricò M; Conter V; Testi A; Barisone E; Casale F; Lo Nigro L; Rondelli R; Basso G; Santoro N; Masera G;
J Clin Oncol; 2001 Mar; 19(5):1297-303. PubMed ID: 11230471
[TBL] [Abstract][Full Text] [Related]
7. Reduced vs. standard dose native E. coli-asparaginase therapy in childhood acute lymphoblastic leukemia: long-term results of the randomized trial Moscow-Berlin 2002.
Karachunskiy A; Tallen G; Roumiantseva J; Lagoiko S; Chervova A; von Stackelberg A; Aleinikova O; Bydanov O; Bajdun L; Nasedkina T; Korepanova N; Kuznetsov S; Novichkova G; Goroshkova M; Litvinov D; Myakova N; Ponomareva N; Inyushkina E; Kondratchik K; Abugova J; Fechina L; Arakaev O; Karelin A; Lebedev V; Judina N; Scharapova G; Spichak I; Shamardina A; Ryskal O; Shapochnik A; Rumjanzew A; Boos J; Henze G;
J Cancer Res Clin Oncol; 2019 Apr; 145(4):1001-1012. PubMed ID: 30840197
[TBL] [Abstract][Full Text] [Related]
8. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
[TBL] [Abstract][Full Text] [Related]
9. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
[TBL] [Abstract][Full Text] [Related]
10. l-asparaginase loaded red blood cells in refractory or relapsing acute lymphoblastic leukaemia in children and adults: results of the GRASPALL 2005-01 randomized trial.
Domenech C; Thomas X; Chabaud S; Baruchel A; Gueyffier F; Mazingue F; Auvrignon A; Corm S; Dombret H; Chevallier P; Galambrun C; Huguet F; Legrand F; Mechinaud F; Vey N; Philip I; Liens D; Godfrin Y; Rigal D; Bertrand Y
Br J Haematol; 2011 Apr; 153(1):58-65. PubMed ID: 21332712
[TBL] [Abstract][Full Text] [Related]
11. Unexpected mortality from the use of E. coli L-asparaginase during remission induction therapy for childhood acute lymphoblastic leukemia: a report from the Taiwan Pediatric Oncology Group.
Liang DC; Hung IJ; Yang CP; Lin KH; Chen JS; Hsiao TC; Chang TT; Pui CH; Lee CH; Lin KS
Leukemia; 1999 Feb; 13(2):155-60. PubMed ID: 10025887
[TBL] [Abstract][Full Text] [Related]
12. [Long-term follow-up of 2 therapeutic programs for the treatment of high-risk childhood acute lymphoblastic leukemia. Experience at the 20 de Noviembre National Medical Center].
de Diego-Floreschapa J; López-Hernández M; Borbolla-Escoboza JR; Trueba-Christy E; Carrillo-Rosales T; González-Avante M
Gac Med Mex; 1999; 135(3):253-8. PubMed ID: 10425822
[TBL] [Abstract][Full Text] [Related]
13. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
[TBL] [Abstract][Full Text] [Related]
14. Outcomes Following Discontinuation of E. coli l-Asparaginase Upon Severe Allergic Reactions in Children With Acute Lymphoblastic Leukemia.
Yen HJ; Chang WH; Liu HC; Yeh TC; Hung GY; Wu KH; Peng CT; Chang YH; Chang TK; Hsiao CC; Sheen JM; Chao YH; Chang TT; Chiou SS; Lin PC; Wang SC; Lin MT; Ho WL; Chen YC; Liang DC
Pediatr Blood Cancer; 2016 Apr; 63(4):665-70. PubMed ID: 26703788
[TBL] [Abstract][Full Text] [Related]
15. High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.
Marshall GM; Dalla Pozza L; Sutton R; Ng A; de Groot-Kruseman HA; van der Velden VH; Venn NC; van den Berg H; de Bont ES; Maarten Egeler R; Hoogerbrugge PM; Kaspers GJ; Bierings MB; van der Schoot E; van Dongen J; Law T; Cross S; Mueller H; de Haas V; Haber M; Révész T; Alvaro F; Suppiah R; Norris MD; Pieters R
Leukemia; 2013 Jul; 27(7):1497-503. PubMed ID: 23407458
[TBL] [Abstract][Full Text] [Related]
16. Minimal residual disease (MRD) measurement as a tool to compare the efficacy of chemotherapeutic drug regimens using Escherichia Coli-asparaginase or Erwinia-asparaginase in childhood acute lymphoblastic leukemia (ALL).
Kwok CS; Kham SK; Ariffin H; Lin HP; Quah TC; Yeoh AE
Pediatr Blood Cancer; 2006 Sep; 47(3):299-304. PubMed ID: 16302217
[TBL] [Abstract][Full Text] [Related]
17. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia.
Sallan SE; Hitchcock-Bryan S; Gelber R; Cassady JR; Frei E; Nathan DG
Cancer Res; 1983 Nov; 43(11):5601-7. PubMed ID: 6352020
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of rubidomycin in induction therapy with vincristine, prednisone, and L-asparaginase for standard risk childhood acute lymphocytic leukemia: results of a Dutch phase III study (ALL V). A report on behalf of the Dutch Childhood Leukemia Study Group (DCLSG).
van der Does-van den Berg A; van Wering ER; Suciu S; Solbu G; van 't Veer MB; Rammeloo JA; de Koning J; van Zanen GE
Am J Pediatr Hematol Oncol; 1989; 11(2):125-33. PubMed ID: 2665546
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of recombinant E. coli asparaginase in children with previously untreated acute lymphoblastic leukemia: A randomized multicenter study of the Dutch Childhood Oncology Group.
van der Sluis IM; de Groot-Kruseman H; Te Loo M; Tissing WJE; van den Bos C; Kaspers GJL; Bierings M; Kollen WJW; König T; Pichlmeier U; Kühnel HJ; Pieters R
Pediatr Blood Cancer; 2018 Aug; 65(8):e27083. PubMed ID: 29727043
[TBL] [Abstract][Full Text] [Related]
20. Treatment of childhood acute lymphoblastic leukemia. Long-term results of the AIEOP-ALL 87 study.
Paolucci G; Vecchi V; Favre C; Miniero R; Madon E; Pession A; Rondelli R; De Rossi G; Lo Nigro L; Porta F; Santoro N; Indolfi P; Basso G; Conter V; Aricò M;
Haematologica; 2001 May; 86(5):478-84. PubMed ID: 11410410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
